Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain

Journal of Pain Research

Volumn 6, Issue , 2013, Pages 319-329

  Hale, Martin E ^a   Nalamachu, Srinivas R ^b   Khan, Arif ^c   Kutch, Michael ^d,e  

^a Gold Coast Research LLC   (United States)

^b Clinical Research   (United States)

^c Northwest Clinical Research Center   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e Applied Clinical Intelligence LLC   (United States)

Author keywords

Chronic low back pain; Conversion and titration; Extended release opioids; Noncancer pain; Opioid rotation; OROS hydromorphone ER

Indexed keywords

HYDROMORPHONE; OPIATE; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC PAIN; CLINICAL PRACTICE; CONSTIPATION; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTRITIS; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; OUTCOME ASSESSMENT; PAIN INTENSITY; PAIN PARAMETERS; PATIENT GLOBAL ASSESSMENT SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM HEMORRHAGE; ROLAND MORSIS DISABILITY QUESTIONNAIRE SCORE; SCORING SYSTEM; SOMNOLENCE; TABLET; TREATMENT DURATION; VOMITING;

EID: 84877892489     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S39980     Document Type: Article

References (59)

1. United States Census Bureau. Preliminary annual estimates of the resident population for the United States, regions, states, and Puerto Rico: April 1, 2000 to July 1, 2010 (NST-PEST2010-01) [webpage on the Internet]; 2002 [updated Feb 2011]. Washington, DC: United States Census Bureau. Available from: http://www.census.gov/popest/research/eval-estimates/ eval-est2010.html. Accessed October 22, 2012.
2. National Center for Health Statistics. Health, United States, 2006. With Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics; 2006. DHS Publication No 2006-1232. Available from: http://www.cdc.gov/nchs/data/hus/ hus06.pdf. Accessed March 8, 2012.
3. Haanpää ML, Backonja MM, Bennett MI, et al. Assessment of neuropathic pain in primary care. Am J Med. 2009;122(Suppl 10):S13-S21.
4. Khouzam RH. Chronic pain and its management in primary care. South Med J. 2000;93(10):946-952.
5. McCarberg BH. Pain management in primary care: strategies to mitigate opioid misuse, abuse, and diversion. Postgrad Med. 2011;123(2): 119-130.
6. Chou R, Huffman LH; for American Pain Society, American College of Physicians. Medications for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med. 2007;147(7): 505-514.
7. Chou R, Fanciullo GJ, Fine PG, et al; for American Pain Society-American Academy of Pain Medicine Opioids Guidelines Panel. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
8. Caldwell JR. Avinza - 24-h sustained-release oral morphine therapy. Expert Opin Pharmacother. 2004;5(2):469-472.
9. Rauck RL. What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Pract. 2009;9(6):468-479.
10. Moore KT, St-Fleur D, Marricco NC, et al. Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteers. J Opioid Manag. 2010;6(5): 351-358.
11. Hays H, Hagen N, Thirlwell M, et al. Comparative clinical efficacy and safety of immediate release and controlled release hydromorphone for chronic severe cancer pain. Cancer. 1994;74(6):1808-1816.
12. Bruera E, Sloan P, Mount B, Scott J, Suarez-Almazor M. A randomized, double-blind, double-dummy, crossover trial comparing the safety and efficacy of oral sustained-release hydromorphone with immediaterelease hydromorphone in patients with cancer pain. J Clin Oncol. 1996;14(5):1713-1717.
13. McCarberg BH, Nicholson BD, Todd KH, Palmer T, Penles L. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey. Am J Ther. 2008;15(4):312-320.
14. Mystakidou K, Clark AJ, Fischer J, Lam A, Pappert K, Richarz U. Treatment of chronic pain by long-acting opioids and the effects on sleep. Pain Pract. 2011;11(3):282-289.
15. Brennan MJ, Lieberman JA 3rd. Sleep disturbances in patients with chronic pain: effectively managing opioid analgesia to improve outcomes. Curr Med Res Opin. 2009;25(5):1045-1055.
16. Fine PG, Mahajan G, McPherson ML. Long-acting opioids and shortacting opioids: appropriate use in chronic pain management. Pain Med. 2009;10(Suppl 2):S79-S88.
17. Pergolizzi JV, Taylor R Jr, Raffa RB. Extended-release formulations of tramadol in the treatment of chronic pain. Expert Opin Pharmacother. 2011;12(11):1757-1768.
18. Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138(3):507-513.
19. Oramorph SR (morphine sulfate) Sustained-Release Tablets, CII [package insert]. Newport, KY: Xanodyne Pharmaceticals,Inc; 2006.
20. MS Contin (morphine sulfate controlled-release) Tablets CII [package insert]. Stamford, CT: Purdue Pharma LP; 2009.
21. Kadian (morphine sulfate) Extended-Release Capsules, for oral use, CII [package insert. Morristown, NJ>: Actavis Elizabeth LLC; 2010.
22. Opana ER (oxymorphone hydrochloride) Extended-Release tablets, for oral use, CII [package insert]. Chadds Ford, PA: Endo Pharmaceuticals,Inc; 2008.
23. Avinza (morphine sulfate extended-release capsules) CII [package insert]. Bristol, TN: King Pharmaceuticals,Inc; 2008.
24. OxyContin (oxycodone hydrochloride controlled-release) Tablets CII [package insert]. Stamford, CT: Purdue Pharma LP; 2010.
25. Embeda (morphine sulfate and naltrexone hydrochloride) Extended- Release Capsules, for oral use, CII [package insert]. Bristol, TN: King Pharmaceuticals; 2009.
26. Exalgo (hydromorphone HCl) Extended-Release Tablets (CII) [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals,Inc; 2012.
27. Duragesic (fentanyl transdermal system) CII [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals,Inc; 2009.
28. Vicodin (hydrocodone bitartrate and acetaminophen tablets, USP) [package insert]. North Chicago, IL: Abbott Laboratories; 2011.
29. Papaleontiou M, Henderson CR Jr, Turner BJ, et al. Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis. J Am Geriatr Soc. 2010;58(7):1353-1369.
30. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ. 2006;174(11):1589-1594.
31. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic noncancer pain: systematic review of efficacy and safety. Pain. 2004;112(3): 372-380.
32. Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage. 2005;29(5 Suppl):S57-S66.
33. Drover DR, Angst MS, Valle M, et al. Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology. 2002;97(4):827-836.
34. Turgeon J, Gröning R, Sathyan G, Thipphawong J, Richarz U. The pharmacokinetics of a long-acting OROS hydromorphone formulation. Expert Opin Drug Deliv. 2010;7(1):137-144.
35. Gupta S, Sathyan G. Providing constant analgesia with OROS ® hydromorphone. J Pain Symptom Manage. 2007;33(2 Suppl):S19-S24.
36. Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer. 1996;78(4):852-857.
37. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38(3):426-439.
38. Palangio M, Northfelt DW, Portenoy RK, et al. Dose conversion and titration with a novel, once-daily, OROS osmotic technology, extended-release hydromorphone formulation in the treatment of chronic malignant or nonmalignant pain. J Pain Symptom Manage. 2002;23(5):355-368.
39. Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Once-daily OROS hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study. Int J Clin Pract. 2007;61(10):1671-1676.
40. Wallace M, Rauck RL, Moulin D, Thipphawong J, Khanna S, Tudor IC. Conversion from standard opioid therapy to once-daily oral extended-release hydromorphone in patients with chronic cancer pain. J Int Med Res. 2008;36(2):343-352.
41. Hale M, Khan A, Kutch M, Li S. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin. 2010;26(6):1505-1518.
42. Hanna M, Thipphawong J; for 118 Study Group. A randomized, doubleblind comparison of OROS(R) hydromorphone and controlled-release morphine for the control of chronic cancer pain. BMC Palliat Care. 2008;7:17.
43. Binsfeld H, Szczepanski L, Waechter S, Richarz U, Sabatowski R. A randomized study to demonstrate noninferiority of once-daily OROS® hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract. 2010;10(5): 404-415.
44. Quigley C, Wiffen P. A systematic review of hydromorphone in acute and chronic pain. J Pain Symptom Manage. 2003;25(2):169-178.
45. Hanna M, Tuca A, Thipphawong J. An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain. BMC Palliat Care. 2009;8:14.
46. Wallace M, Skowronski R, Khanna S, Tudor IC, Thipphawong J. Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127). Curr Med Res Opin. 2007;23(5):981-989.
47. Wallace M, Thipphawong J. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain. Pain Med. 2010;11(10): 1477-1488.
48. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain. 1992;49(1):87-91.
49. Mercadante S. Opioid rotation for cancer pain: rationale and clinical aspects. Cancer. 1999;86(9):1856-1866.
50. Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg. 2000;90(4):933-937.
51. Slatkin NE. Opioid switching and rotation in primary care: implementation and clinical utility. Curr Med Res Opin. 2009;25(9):2133-2150.
52. Fine PG, Portenoy RK; for Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing best practices for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38(3):418-425.
53. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35(2):253-259.
54. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13(3):293-308.
55. Mahler DL, Forrest WH Jr. Relative analgesic potencies of morphine and hydromorphone in postoperative pain. Anesthesiology. 1975;42(5): 602-607.
56. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-158.
57. Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manage. 2003;25(5):406-411.
58. Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short-term administration: effect of age, gender, and race. Clin Pharmacol Ther. 2003;74(2):102-112.
59. Ting N. Dose Finding in Drug Development. New York, NY: Springer; 2006.